Ole Østergaard Thomsen

7.5k citations

88 papers · 5.6k indexed · 3 hit papers · h-index 31

Impact in

Genetics top 0.2%
- Inflammatory Bowel Disease
Gastroenterology top 0.5%

Papers in

Genetics 55
- Inflammatory Bowel Disease 55
- Chronic Lymphocytic Leukemia Research 6
Gastroenterology 9

Co-authors: Jørn Brynskov Casper Steenholdt Mark Ainsworth Klaus Bendtzen Stefan Schreiber Ralph Bloomfield William J. Sandborn Ian C. Lawrance
Journals: Scandinavian Journal of Gastroenterology (10 papers)Gastroenterology (8 papers)Journal of Crohn s and Colitis (7 papers)The American Journal of Gastroenterology (7 papers)Alimentary Pharmacology & Therapeutics (6 papers)
Partner nations: Denmark United Kingdom Germany

In The Last Decade

Ole Østergaard Thomsen

86 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial 2013 · 361 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Gut
2011 Journal of Clinical Gastroenterology
2007 New England Journal of Medicine

Peers

Countries citing papers authored by Ole Østergaard Thomsen

Since Specialization

Citations

This map shows the geographic impact of Ole Østergaard Thomsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ole Østergaard Thomsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ole Østergaard Thomsen more than expected).

Fields of papers citing papers by Ole Østergaard Thomsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ole Østergaard Thomsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ole Østergaard Thomsen. The network helps show where Ole Østergaard Thomsen may publish in the future.

Co-authors

The 25 scholars most cited alongside Ole Østergaard Thomsen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ole Østergaard Thomsen Line = papers co-authored together Ole Østergaard Thomsen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	P471. Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients Journal of Crohn s and Colitis ·Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Mark Ainsworth	2015	1
2	Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy The American Journal of Gastroenterology ·Katrine Risager Christensen, Casper Steenholdt, Sine Buhl, Mark Ainsworth, Ole Østergaard Thomsen, Jørn Brynskov	2015	19
3	Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial BMJ Open ·Sine Buhl, Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen, Mark Ainsworth	2014	16
4	Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial Gut ·Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm, Jakob Kjellberg, Klaus Bendtzen, Mark Ainsworth Hit paper breakdown →	2013	361
5	Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease Alimentary Pharmacology & Therapeutics ·Casper Steenholdt, Morten Svenson, Klaus Bendtzen, Ole Østergaard Thomsen, Jørn Brynskov, Mark Ainsworth	2011	124
6	Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease Journal of Crohn s and Colitis ·Casper Steenholdt, Morten Svenson, Klaus Bendtzen, Ole Østergaard Thomsen, Jørn Brynskov, Mark Ainsworth	2011	56
7	World Gastroenterology Organisation Global Guideline Journal of Clinical Gastroenterology ·Greger Lindberg, Saeed Hamid, Peter Malfertheiner, Ole Østergaard Thomsen, Luis Bustos Fernández, James Garisch, Alan Thomson, Khean‐Lee Goh, Rakesh Tandon, S S Fedail, Benjamin CY Wong, Aamir Ghafoor Khan, Justus Krabshuis, Anton LeMair Hit paper breakdown →	2011	449
8	Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease Scandinavian Journal of Gastroenterology ·Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Ole Østergaard Thomsen, Mark Ainsworth	2010	153
9	Maintenance Therapy with Certolizumab Pegol for Crohn's Disease New England Journal of Medicine ·Stefan Schreiber, Mani Khaliq-Kareemi, Ian C. Lawrance, Ole Østergaard Thomsen, Stephen B. Hanauer, Juliet McColm, Ralph Bloomfield, William J. Sandborn Hit paper breakdown →	2007	766
10	A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease Gastroenterology ·Stefan Schreiber, Paul Rutgeerts, Richard N. Fedorak, Munaa Khaliq–Kareemi, Michael A. Kamm, Michel Boivin, Çharles N. Bernstein, Michael Staun, Ole Østergaard Thomsen, Alison Innes	2005	442
11	Corticosteroids for maintenance of remission in Crohn's disease Cochrane Database of Systematic Reviews ·A. Hillary Steinhart, Klaus Ewe, Anne M. Griffiths, R Modigliani, Ole Østergaard Thomsen	2003	146
12	Thiopurine methyltransferase genotype distribution in patients with Crohn's disease Alimentary Pharmacology & Therapeutics ·Lene Ørskov Reuther, Jesper Sonne, Nadja Larsen, Jens Frederik Dahlerup, Ole Østergaard Thomsen, Kjeld Schmiegelow	2002	27
13	A Comparison of Budesonide and Mesalamine for Active Crohn's Disease New England Journal of Medicine ·Ole Østergaard Thomsen, Antoine Cortot, D P Jewell, John Wright, Trevor A. Winter, Fernando Tavarela Veloso, Morten Vatn, Tore Persson, Eva Pettersson	1998	228
14	Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut ·Robert Löfberg, Paul Rutgeerts, H Malchow, C. B. H. W. Lamers, Åke Danielsson, Gunnar Olaison, D P Jewell, Ole Østergaard Thomsen, H. Lorenz‐Meyer, H. Goebell, Humphrey Hodgson, Tore Persson, Cecilia Seidegard	1996	157
15	Increased hepatic urea synthesis in patients with active inflammatory bowel disease Journal of Hepatology ·Charlotte Lundsgaard, Ole Hamberg, Ole Østergaard Thomsen, Ole Haagen Nielsen, Hendrik Vilstrup	1996	21
16	Budesonide versus prednisolone retention enemas in active distal ulcerative colitis Alimentary Pharmacology & Therapeutics ·Robert Löfberg, Ole Østergaard Thomsen, Ebbe Langholz, R Schiöler, Åke Danielsson, Ole B. Suhr, H. Graffner, Lars Påhlman, Peter Matzen, J Møller-Petersen, Lars Halvorsen, N Hovdenak, Roger Wïllén, Tore Persson, Cecilia Seidegard	1994	87
17	Prevention of Duodenal Ulcer Recurrence with Penicillin: A Double-Blind, Placebo-Controlled Trial Scandinavian Journal of Gastroenterology ·S. J. Rune, T. Justesen, Jens Hansen, Thøger Gorm Jensen, Jens Eriksen, Ole Østergaard Thomsen, J. Scheibel, O Bonnevie, Annie Bremmelgaard, M. Vilien, Svend Knuhtsen, L Elsborg, K. Lauritsen, Henrik R. Wulff	1993	10
18	What do gastroenterologists in Europe tell cancer patients? The Lancet ·Ole Østergaard Thomsen, Henrik R. Wulff, A. Martin, PeterA. Singer	1993	155
19	Final Report on a Placebo-Controlled, Double-Blind, Randomized, Multicentre Trial of Cyclosporin Treatment in Active Chronic Crohn's Disease Scandinavian Journal of Gastroenterology ·Jørn Brynskov, L Freund, Sten Nørby Rasmussen, K. Lauritsen, Ove B. Schaffalitzky de Muckadell, C. N. Williams, A. S. Macdonald, R Tanton, Francisco Fidencio Cons Molina, Mauro Campanini, Paola Bianchi, T Ranzi, F. Quarto di Palo, A Malchow-Møller, Ole Østergaard Thomsen, Ulrik Tage‐Jensen, V. Binder, P Riis	1991	68
20	Comparison of vanadate and ouabain effects on liver hemodynamics and bile production in the perfused rat liver. Journal of Pharmacology and Experimental Therapeutics ·Ole Østergaard Thomsen, J. A. Larsen	1982	7

About Ole Østergaard Thomsen

Ole Østergaard Thomsen is a scholar working on Genetics, Gastroenterology, Epidemiology, Immunology and Genetics, having authored 88 papers that have together received 5.6k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (55 papers), Microscopic Colitis (36 papers), Immunodeficiency and Autoimmune Disorders (22 papers), Eosinophilic Esophagitis (8 papers), Drug Transport and Resistance Mechanisms (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Autoimmune and Inflammatory Disorders (6 papers) and Biosimilars and Bioanalytical Methods (5 papers). The work is most often cited by research in Genetics (3.8k citations), Gastroenterology (569 citations), Epidemiology (3.1k citations), Immunology (1.4k citations) and Surgery (1.6k citations). Ole Østergaard Thomsen has collaborated with scholars based in Denmark, United Kingdom and Germany. Frequent co-authors include Jørn Brynskov, Casper Steenholdt, Mark Ainsworth, Klaus Bendtzen, Stefan Schreiber, Ralph Bloomfield, William J. Sandborn, Ian C. Lawrance, Stephen B. Hanauer and Juliet McColm. Their work appears in journals such as Scandinavian Journal of Gastroenterology, Gastroenterology, Journal of Crohn s and Colitis, The American Journal of Gastroenterology and Alimentary Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact